mbilical cord-derived mesenchymal stromal cells therapy for SARS-CoV-2 infection (COVID-19) related Acute Respiratory Distress Syndrome
Phase 1
Completed
- Conditions
- SARS-CoV-2 infection(COVID-19) related Acute Respiratory Distress Syndrome (ARDS)
- Registration Number
- JPRN-jRCT1080225369
- Lead Sponsor
- Human Life CORD Japan Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 12
Inclusion Criteria
SARS-CoV-2 positive with RT-PCR test or antigen test.
ARDS as defined by the Berlin definition.
Receiving standard of care for COVID-19 and ARDS.
Exclusion Criteria
Receiving immunosuppressant drug except steroids.
Increased dose of steroids.
Malignant tumor, Acute myocardial infarction, Pulmonary hypertension, Dialysis.
Not SARS-CoV-2 infection.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method